Africa Corporate Wellness Market, by End User, 2018-2027
| Label | USD Million |
|---|---|
| 2018 | 274.90155008361194 USD Million |
| 2019 | 291.8894025756228 USD Million |
| 2020 | 310.445039750214 USD Million |
| 2021 | 330.7586547258553 USD Million |
| 2022 | 353.82662294355606 USD Million |
| 2023 | 372.0930833235512 USD Million |
| 2024 | 392.17887597356025 USD Million |
| 2025 | 414.31132326734513 USD Million |
| 2026 | 438.7521671358023 USD Million |
| 2027 | 465.8036431339544 USD Million |
| 2028 | 495.8157729827009 USD Million |
| 2029 | 529.1951488472226 USD Million |
| 2030 | 596.9198501545767 USD Million |
| 2031 | 637.7051997844341 USD Million |
| 2032 | 681.2497420009615 USD Million |
Data Source: Wantstats Repository
Market Dynamics
Germany has the sixth-largest dry eye syndrome market in the world. The country has a growing number of individuals suffering from dry eye syndrome due to age, environmental exposure, hormonal imbalance and other underlying conditions. It is estimated that dry eye syndrome affects around 10% of the German population, leading to strong demand for treatments. The German dry eye syndrome market was valued at US$350 million in 2018, and is likely to experience healthy growth during the forecast period (2018-2032), primarily due to increasing awareness about the condition, availability of advanced treatments such as artificial tears and other drugs, and the rising prevalence of dry eye syndrome in the country. The reimbursement coverage for dry eye syndrome treatments is also improving in Germany, as it increases accessibility and affordability of treatments. Moreover, increasing prevalence of autoimmune diseases such as Sjogren's Syndrome is also driving the demand for dry eye syndrome treatments. The key stakeholders in the German dry eye syndrome market that have invested in the research and development of dry eye syndrome drugs, and infrastructure to promote its awareness and treatments, include Novartis AG, Bayer AG, and Regeneron Pharmaceuticals, Inc, among others.
The key challenges in the market include lack of awareness and availability of treatments for the condition. Additionally, high costs of treatment resulting from limited insurance coverage is slowing adoption of dry eye syndrome treatments in Germany. To overcome this challenge, companies in the market are introducing new dry eye syndrome drug formulations and making them available in better dosage forms, such as ointments, gels, and drops. They are also launching aggressive promotional campaigns, especially for eye care professionals, to increase awareness of the condition. Additionally, key players operating in this market are slowly building collaborations with health insurers to improve reimbursement coverage. The German dry eye syndrome market is thus expected to experience healthy growth during the forecast period (2018-2032). With the increasing awareness about the condition, improved reimbursement policies, and rising adoption of treatments, the demand and availability of dry eye syndrome treatments are likely to improve in Germany.
Research Methodology
Figures reflect Wantstats’ original market research and forecasting models, compiled as part of the Wantstats research archive and published in 2023.
Unlock the Full Data
Get This Chart
Access the complete chart and underlying data to support your research, analysis, and business decisions.
Powering the world's best teams.
From next-gen startups to established enterprises.
Get in Touch
Let's work together
support@wantstats.comSee our work in action
Start your data driven journey with us!
What our clients say
Trusted by forward-thinking businesses
for data-driven intelligence



